Online inquiry

IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10221MR)

This product GTTS-WQ10221MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets RHD gene. The antibody can be applied in prevention of feto-maternal allo-immunization in RhD- women research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001127691.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6007
UniProt ID Q02161
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10221MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7948MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ9065MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ4719MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ12262MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MRA
GTTS-WQ13536MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ1571MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ13979MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ10804MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA M777-16-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW